is doing DD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It does look promising.
But there is always a but. It's the 4th "round of warrants" and so far they let them all expire.
https://www.otcmarkets.com/filing/html?id=12983098&guid=48KMUKBJJmYeh3h
Great company, great BoD, great potential!
But imo the problem is how long could this take and the float.
CFGN going up. I'm not sure I understand what's happening.
But me neither, going to be watching closely the MM games here.
Well the positive is that the spread is getting tighter.
But the risk is starting to be pretty big imo.
But 1 nice PR could make it explode so much!
glta!
VNDM and CFGN were at 0.25 since the name change.
CFGN is now at 0.20.
................
Each new warrant, denominated as Class D, is exercisable through September 28, 2018 (subsequently extended to November 30 2018) to purchase one unit for $1.00, each unit consisting of one share of Common Stock and a warrant to purchase one share of Common Stock at a price of $2.00 per share through January 31, 2019."
Maybe it's someone loading before November 30th?
It looked like retail to me... 10k shares.
10k ask is gone, I noticed it at around 30 minutes before close.
Each new warrant, denominated as Class D, is exercisable through September 28, 2018 (subsequently extended to November 30 2018) to purchase one unit for $1.00, each unit consisting of one share of Common Stock and a warrant to purchase one share of Common Stock at a price of $2.00 per share through January 31, 2019."
https://www.otcmarkets.com/filing/html?id=12983098&guid=uZ6MUqLK5w9BHth
Manganella Frank J
https://www.otcmarkets.com/filing/html?id=13050519&guid=wuFMUFOezEQDath
FRANCIS J MANGANELLA
CORPORATE FINANCE & BUSINESS DEVELOPMENT
Francis has nearly 30 years of Wall Street experience, along with spending several years with numerous entrepreneurial ventures in the financial services technology and interactive technology sector. His previous roles included global responsibilities with global investment banks, including debt capital markets and credit portfolio management. His entrepreneurial roles have focused on business development for several startups, with responsibilities including strategic development, customer acquisition and equity and financial management. Currently, Francis is a stakeholder in several cannabis companies, across numerous verticals including technology, life sciences and marketing.
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
Nexien Biopharma Inc. (OTC: NXEN) announced it acquired New Jersey-based CRx Bio Holdings. The combined companies will formulate FDA approved cannabinoid therapies with the objective of enhancing the bioavailability, pharmacokinetics, and pharmacodynamics of cannabinoids.
Alex Wasyl, CEO Nexien Biopharma told us that “The acquisition...is a major step in developing FDA approved cannabinoid therapeutics and optimized delivery system platforms. As a serial life sciences entrepreneur, I founded CRx with this vision, based on my 10 years of research in cannabinoid and related sciences, with the goal of creating real pharmaceutical medicines.”
Considering all the shares they are currently acquiring I can understand why they want to remain under the radar for the moment. If the insiders are loading at these prices I think it is a good indicator.
Imo, let the chart stabilize, let the insiders acquire all the shares they want, don't put out fluffy PRs saying "news coming soon" for example and once the pps has to go up it will go up.
I like to remind myself of ALL the shares they acquired, the post poned warrants and what Bankier managed to do with EBBU.
If bottom is confirmed I will be more than happy to accumulate as much as I can.
And big pps change is part of the joys of investing in a tiny float. Once bottom is confirmed, things will start to look very nice pretty soon imo. Time will tell.
Today was a nice day imo.
Low volume but nothing weird and no t-trade. I like it.
Very impressive indeed.
Brief quote:
Professional & Community Activities:
American Intellectual Property Law Association
American Bar Association
Pennsylvania Bar Association
American Society of Pharmacology and Experimental Therapeutics
Biophysical Society
Mid-Atlantic Pharmacology Society
If that is the case, I wonder why were the form 4s made before the CRx people sold their shares in the float. Why not wait to make those form 4s and acquire shares at a lower price?
CWEB.c chart 30min candles above 50ma. (13.08 CAD)
Some would say the bulls are in control.
Canadian IPO was at 10$ CAD, it went down to 9.05 on that day and then it went up and higher.
10$ CAD = 7.61$ USD
9.05$ CAD = 6.89$ USD
I expect a bounce around these prices.
Nice, thanks. $NXEN!
i-box update maybe?
Or simply delete the old info?
2soon?
Founded in 2010, The Arcview Group is the first and largest group of investors dedicated to the legal cannabis industry.
Forbes Magazine named Arcview among the top 5 financial firms in the cannabis sector.
Alain Bankier
Investor
Alain Bankier (NXEN CEO) appears on EBBU form4
https://www.sec.gov/Archives/edgar/data/1634129/000163412918000003/xslFormDX01/primary_doc.xml
and:
Oct 15, 2018, 07:00 ET
Canopy Growth to Acquire Assets of Colorado-Based Hemp Innovator Ebbu
I agree. Wouldn't tweeting some "insider info" or email them to a retail investor look bad to the eyes of the CSE?
Interesting day. CWEB double bottomed it seems. Finally! imo.
Brutal day for cannabis in general though. But if the new bottoms are in, time to go up.
Small OS can be crazy rides!
Once I heard some serious people say that the cannabis sector is in a bubble and through that bubble many will fall and few will rise. I do believe Charlotte's Web will be one of the long term winners. I generally don't hold for years but this one is different.
jmho
On September 12, 2018, the registrant extended the expiration date of its Class D Warrants, currently September 28, 2018, to November 30, 2018. Each Class D Warrant is exercisable to purchase one unit for $1.00, each unit consisting of one share of common stock and a warrant to purchase one share of common stock at a price of $2.00 per share through January 31, 2019.
next resistance: 10'000$?
could double bottom at 0.005???
"The stock market is a device for transferring money from the impatient to the patient." - Warren Buffett
A key motivator for my investment was Intiva's objective of "developing real pharmaceuticals, based on real science," which I believe is the future of this (cannabis) industry.
Yes, it all happened during the name changing process so I could not sell a single share! Now I protect myself from a similar situation happening and I buy shares of the new ticker.
Name change was announced at around 0.35? So 5000% would be 17.50$. This is mathematics, not predictions btw.
With the amazing DD, the acquired shares and the postponed warrants at a 100% higher price, this should be a very good trade as well.
And if the name change was approved by FINRA, I think we have reasons to believe they are going on the CSE very soon.
Once I bought shares from a company who changed name the next day. The pps did over 5000% and I could not sell! Ever since that day I buy pre name change and post name change.
Best trade of my life and I couldn't sell! Never again.
I wonder how many will enjoy their Tuesday morning:
https://www.nasdaq.com/press-release/nio-inc-to-report-third-quarter-2018-financial-results-on-november-6-2018-20181019-00104
I don't do one night stands when there is a -name change- and I never do morning quickies with my "duct taped renegade computer". Maybe corporate actions are much quicker with prestigious accounts? And since the "axe A" I buy pre-name change and post-name change.
And if I ever do a morning quicky I wouldn't talk about it here. I may get bored more easily than the oracle but flash speed is not my forte. And this one is not sea-bee-dee water or whatever.
I've been on many forums who had nothing to do with the market and I noticed they all go through cycles and the good old days are always good. I might try to find some cache pages to see how the good old days were here.
Also, the tech bubble, I wasn't there to witness it, but surely trading bubbles can be profitable if you don't get too greedy?
I will copy paste some parts of the 10k I like (not trying to sell anything here!!! just discussing)
The Company’s business objective is to pursue the formulation and development of cannabinoid-based drugs for diseases, disorders and medical conditions. At present, the Company owns two exclusive licenses covering extensive intellectual property. The Company has also filed four utility patent applications with the U.S. Patent Office and one international patent application under the Patent Cooperation Treaty. The utility patent applications and the international patent application cover formulations that include cannabinoids and/or other substances, including terpenes formulated for the purpose of treating various medical conditions and disorders.
Terpenes are a large and diverse class of organic compounds, produced by a variety of plants. The name “terpene” is derived from the word “turpentine”. In addition to their roles as end-products in many organisms, terpenes are major biosynthetic building blocks within nearly every living creature. Terpenes are the primary constituents of the essential oils of many types of medical plants and flowers. Essential oils are used widely in, among other things, medicine and alternative medicines. Terpenes are also constituents of the cannabis plant, which contains an estimated 111 cannabinoids, compounds unique to the cannabis plant.
In March 2017, we entered into a license agreement with Kotzker Consulting, LLC (the “Kotzker License Agreement”), an entity founded, and related to certain intellectual property developed, by Pennsylvania-based Dr. Joseph Morgan. The intellectual property includes patent applications relating to the use of cannabinoid receptor modulators and/or terpenes in acute treatment situations during exposure to organophosphorus nerve agents and/or organophosphorus insecticides (the “Kotzker Development Project”). The Company’s patent counsel assumed responsibilities for the Kotzker Development Project patent applications, and has continued efforts to obtain patent protection on the invention. In furtherance of these efforts, a continuation application was filed in July 2018 and the Company is awaiting a response from the United States Patent and Trademark Office (USPTO).
Organophosphorus nerve agents are highly poisonous chemicals that work by preventing the nervous system from working properly and include tabun (Agent GA), sarin (Agent GB), soman (Agent GD), and Agent VX. Nerve agents and other organophosphate pesticides cause acetylcholinesterase inhibition, resulting in signs and symptoms such as pinpoint pupils, eye pain, sweating, drooling, tearing, vomiting, and seizure, also known as Pesticide Syndrome.
Organophosphorus insecticides are chemicals used to kill many types of insects. These chemicals account for a large share of all insecticides used in the United States, including those used on food crops. Most home uses of organophosphorus insecticides have been phased out in the United States. Certain organophosphorus insecticides (e.g., malathion and naled) are also used for mosquito control in the United States.
We believe that a cannabinoid-based drug could be beneficial to treat the symptoms caused by organophosphorus nerve agents and we are hopeful that the regulatory pathway to treat the condition will be as expeditious as possible based upon the potential threat posed by the use of organophosphorus nerve agents by terrorists and countries.
Because of the implications of a nerve agent drug candidate for homeland defense, first responders and military applications, we may also seek government grants for funding the pre-clinical studies or clinical trials for this drug candidate. The Company has not investigated the existence or availability of any such grants, and there can be given no assurance that the Company will be able to obtain such grants, if available.
In February 2017, a provisional U.S. patent application was filed relating to the use of cannabinoid receptor modulators and/or terpenes to treat myotonic and muscular diseases such as dystrophia diseases (the “Sharir Development Project”). Our patent application relates to methods and compositions for treating such diseases with the use of cannabinoids and covers the administration of the drug(s) by such delivery systems as topical, oral, nasal, inhalation or a combination thereof. On February 19, 2018 a regular utility (non-provisional) U.S. Patent Application was filed relating to the use of cannabinoids and/or terpenes to treat dystrophies and myotonia. The application has been assigned U.S. Patent Application No. 15/899,160.
Myotonic dystrophy (“DM”) is a genetic disorder that affects muscular function. Myotonia and myalgia are the most common symptoms in both DM type 1 (DM1) and type 2 (DM2). Other symptoms include anxiety and sleeplessness.
The use of cannabinoid receptor modulators and/or terpenes for clinical symptom relief in DM patients has not been explored. Current scientific knowledge of the effects of cannabis on skeletal muscles or other multiple system symptoms in DM is rather limited. However, some anecdotal reports suggest that cannabis may be supportive in relief of the most common symptoms in both DM1 and DM2. Unfortunately, currently there is no standard treatment for these symptoms.
In July 2018, the Company retained Dr. Benedikt Schoser, a world-renowned expert in DM, to advise the Company. To elicit further information regarding whether DM patients have had any experience with cannabis and if so whether such experience has resulted in any symptom relief, a questionnaire was sent to a number of DM 1 and DM 2 patients by patient organizations. The results of the questionnaire suggest further exploration is appropriate.
CRANBURY, N.J. and Mendoza, ARGENTINA, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells. Patients treated with AT-GAA for up to 18 months showed improvements in six-minute walk test (6MWT) distance and other measures of motor function and muscle strength, stability or increases in forced vital capacity (FVC), and durable reductions in biomarkers of muscle damage and disease substrate. These clinical results are being featured at the 23rd International Annual Congress of the World Muscle Society in an oral platform presentation today, Friday October 5, 2018 at 12:20am ART (11:20am EDT).
The presentation will be given by Professor Benedikt Schoser, senior consultant at the Friedrich-Baur-Institute, Dept. of Neurology at the Ludwig-Maximilians-University of Munich, Germany and Principal Investigator in the ATB200-02 study
As of June 30, 2018, we had $819,739 in cash and cash equivalents. Through June 2018, we have raised approximately $2.1 million in equity under private placement offerings. We believe that current cash is sufficient to start our Kotzker and Sharir Development Projects and fund our operations and capital requirements through the remainder of calendar 2018. We estimate that we will require additional capital of approximately $1.5 million for the first nine months of calendar 2019.
The Company has applied to list its shares of Common Stock on the Canadian Securities Exchange (“CSE”). The CSE has not yet conditionally approved the listing of the Common Stock and listing is subject to the Company fulfilling all of the listing requirements of the CSE. Prior to making this application, the Company has not been subject to the continuous and timely disclosure requirements of Canadian securities laws or other rules, regulations and policies of the CSE. We are working with our legal, accounting and financial advisors to identify those areas in which changes should be made to our financial management control systems to manage our obligations as a public company on the CSE.
Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies may compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to our research projects.
In the event an active trading market develops for our Common Stock, the market price may, from time-to-time, be volatile.
In the event an active trading market develops for our Common Stock, the market price of our Common Stock may be highly volatile. Some of the factors that may materially affect the market price of our Common Stock are beyond our control, such as changes in conditions or trends in the industry in which we operate, general market and economic conditions both in the United States and globally, as well as the number of our shares of Common Stock being purchased and sold at any particular time. These factors may materially adversely affect the market price of our Common Stock, regardless of our historic business performance or future business prospects. In addition, the public stock markets have experienced and may be expected to experience extreme price and trading volume volatility. These market fluctuations may adversely affect the market price of our Common Stock.
A large number of additional shares will be available for resale into the public market pursuant to Rule 144, which may cause the market price of our Common Stock to decline significantly.
Sales of a substantial number of shares of our Common Stock in the public market will become available pursuant to Rule 144 promulgated by the SEC under the Act, and could adversely affect the market price of our Common Stock. As of September 25, 2018, we have 44,448,496 shares of Common Stock outstanding, of which 43,071,470 are restricted due to applicable federal securities laws. As restrictions on the resale of shares of Common Stock expire, pursuant to the provisions of Rule 144 or otherwise, the market price could drop significantly if the holders of these restricted shares sell them or are perceived by the market as intending to sell them at any given date or over any particular period of time.
Our directors and executive officers and present stockholders holding more than 5% of our Common Stock will own of record and beneficially, in the aggregate, approximately 68% of our outstanding Common Stock. As a result, if these stockholders were to choose to act together, they would be able to exercise considerable influence over all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions, such as a merger or other sale of our Company or all or a significant percentage of our assets. This concentration of ownership could limit your ability to influence corporate matters and may have the effect of delaying or preventing a third party from acquiring control over us. For information regarding the ownership of our outstanding stock by our executive officers and directors and their affiliates, see the disclosure under Item 12 - “ Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.”
We cannot assure you that the interests of our management and affiliated persons will coincide with the interests of other stockholders. As long as our management and affiliated persons collectively control a substantial portion of our Common Stock, these individuals and/or entities controlled by them, including INTIVA USA Inc., will continue to collectively be able to strongly influence or effectively control our decisions.
Our Common Stock is thinly traded, so stockholders may be unable to sell at or near ask prices, or at all, if they need to sell shares to raise money or otherwise desire to liquidate their shares.
Our Common Stock is “thinly-traded,” meaning that the number of persons interested in purchasing our Common Stock at or near ask prices at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours, or purchase or recommend the purchase of our shares until such time as we become more seasoned and viable. As a consequence, there may be periods of several days or longer when trading activity in our Common Stock is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on its share price. We cannot give stockholders any assurance that a broader or more active public trading market for our Common Stock will develop or be sustained, or that current trading levels will be sustained.
We cannot assure you that the interests of our management and affiliated persons will coincide with the interests of other stockholders.
Period High Low
Year Ended June 30, 2017:
First Quarter $ 0.42 $ 0.0006
Second Quarter $ 0.1014 $ 0.0402
Third Quarter $ 0.1752 $ 0.012
Fourth Quarter $ 2.7599 $ 0.054
Year Ended June 30, 2018:
First Quarter $ 4.4999 $ 0.69
Second Quarter $ 5.95 $ 0.792
Third Quarter $ 6.00 $ 1.21
Fourth Quarter $ 2.7599 $ 0.054
Recent Sales of Unregistered Securities
During the quarter ended June 30, 2018 we issued and sold the unregistered securities set forth in the table below.
Date Persons or Class of Persons Securities Consideration
4/1/2018 through
6/30/2018 37 accredited investors 692,400 shares of Common Stock $ 265,992
As a relatively new business engaged in start-up operations and activities, we will require substantial additional funding to successfully complete any of our drug development projects. At present, we cannot estimate the substantial capital requirements needed to secure regulatory approvals for our drug candidates. Nevertheless, we estimate we will need to raise at a minimum $1.5 million during the next 12 months to commence our drug development projects and fund the operating costs related to being a public company.
At June 30, 2018, we had working capital of $745,954, and cash of $819,739, as compared to working capital of $173,702 and cash of $242,778 at June 30, 2017. The increase in both working capital and cash was due primarily to the Company’s receipt of cash from sales of its Common Stock. While operating and investing activities used cash of $923,242 during fiscal 2018, $1,500,203 was provided through sales of Common Stock. In comparison, operating and investing activities used cash of $333,177, while financing activities provided cash of $575,955 during fiscal 2017.
Notwithstanding our success in raising gross proceeds of $2.1 million from the private sale of equity securities through June 30, 2018
On September 12, 2018, the registrant extended the expiration date of its Class D Warrants, currently September 28, 2018, to November 30, 2018. Each Class D Warrant is exercisable to purchase one unit for $1.00, each unit consisting of one share of common stock and a warrant to purchase one share of common stock at a price of $2.00 per share through January 31, 2019.
Any additional equity financing may be dilutive to our stockholders, new equity securities may have rights, preferences or privileges senior to those of existing holders of our shares of Common Stock. Debt or equity financing may subject us to restrictive covenants and significant interest costs.
To date, we raised approximately $2.1 million, in equity capital (including exercised warrants) and we may be expected to require up to an additional $1.5 million in capital during the next 12 months to fully implement our business plan and fund our operations.
On February 28, 2018, we obtained a worldwide exclusive license with respect to a proprietary delivery system for cannabinoid-based medications. We paid $35,000 upon execution of the agreement, and payments of $30,000 and $35,000 are required by August 31, 2018 and February 28, 2019, respectively. On September 18, 2018, the agreement was amended and the licensor has agreed to extend the $30,000 payment originally due August 31, 2018 to a $10,000 payment due November 1, 2018 and a $20,000 payment due February 28, 2019. The $35,000 payment originally due February 28, 2019 is now due August 31, 2019. We are also required to pay milestone payments once we have obtained regulatory approval of pharmaceutical licensed products and royalties based upon sales of licensed products. We may grant sublicenses under the terms of our agreement.
June 30, 2018 June 30, 2017
Assets
Current Assets
Cash $ 819,739 $ 242,778
Total Assets $ 1,272,321 $ 773,692
Current Liabilities
Accounts payable and accrued expenses $ 88,785 $ 210,405
Total current liabilities 88,785 210,405
Net loss $ (1,283,197 ) $ (191,432 )
In January 2018, BioPharma completed a unit private placement of Common Stock and Warrants at a price of $2.10 per unit. Each Unit consisted of two shares of Common Stock and one Warrant to purchase an additional share of common stock at a price of $2.90 per share for a term of six months commencing with the date of acceptance of the underlying subscription agreement.
In my very humble opinion there might be a nice potential for a short term investment. Considering the fact that many people consider the whole sector overvalued these days is important for 2 reasons, imo.
Good investment: because the whole sector is overvalued and this one has not started yet.
Short term: because the whole sector is overvalued.
And this is otc, nothing else than over the counter. So I would add another time: short term. Because better be safe than sorry.
Depending on the entry, if there is one, I would suggest to trade the wave, if there is one, and sell. Then wait to see the market decide where the bottom is and if the company is worth re-investing in, then it will be a whole other trade. I've never been to Omaha, but I doubt the oracle likes the sector.
Looking at the chart I think that perhaps the company needs money for their expensive scientific researches. Could there be possible hints in the latest 10k?
But yes, short term investment, ride the wave, if there is something behind maybe go back in.
jmho
A certain msg has been caught when I was thinking of possible quick profits. I will mention that my intentions were to share a possible opportunity.
pps did 0.09 to 6.00 when COSOS updated in March 2017. (not in a straight line)
https://www.otcmarkets.com/filing/html?id=12983098&guid=L2lMUpu8ZQCpV3h
And they applied in August to go on the CSE.
From the recent 10k
https://www.otcmarkets.com/filing/html?id=12983098&guid=L2lMUpu8ZQCpV3h
BioPharma was incorporated under the laws of the State of Colorado on March 27, 2017
Usually 2 to 5ish business days.
But with AX-XA it took very long. And I would like to be able to sell my shares if they reach 6$ again.
Merger news:
effective Oct. 19,2018 Intiva BioPharma Inc., NTVA, will change to Nexien BioPharma Inc., NXEN:
http://otce.finra.org/DLSymbolNameChanges
https://www.otcmarkets.com/stock/NTVA/security
Float
2,710,691
09/25/2018
https://www.otcmarkets.com/stock/NTVA/news
Latest 10k:
https://www.otcmarkets.com/filing/html?id=12983098&guid=L2lMUpu8ZQCpV3h
https://www.canna-tech.co/speakers/alain-bankier/
I'm buying much more shares tomorrow with the new name. Going to try to get the 1st ever NXEN shares out.
Corporate actions sometimes can take too much time.
jmho
DENVER, CO / ACCESSWIRE / August 22, 2018 / INTIVA BioPharma Inc. ("INTIVA" or the "Company") (OTCQB: NTVA) announced today that it has filed a preliminary non-offering prospectus with certain securities regulators in Canada and has filed a listing application to list its common shares with the Canadian Securities Exchange ("CSE").